Enzomenib Receives FDA Breakthrough Therapy Designation
Sumitomo Pharma America says the FDA granted breakthrough therapy designation to enzomenib (DSP-5336) for treatment of R/R KMT2A-rearranged acute leukemia.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.